A settlement agreement has been signed between Natco Pharma and Onyx Therapeutics Inc. on patent litigation related to generic versions of 10mg, 30mg and 60mg of Kyprolis. Natco has partnered with Breckenridge Pharmaceutical, Inc., who will market the product in the United States.